TEVA Pharmaceutical Industries (TEVA) risk factors

Item 1A of every TEVA Pharmaceutical Industries Ltd. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open TEVA in Gloom →

TEVA Pharmaceutical Industries' chart, financials and news, free in your browser.Open TEVA in Gloom →

FY2025 10-K risk factors
50 risks9 new5 dropped22 reworded
Teva faces intensifying competition for growth engines like AUSTEDO, AJOVY, and UZEDY from well-established rivals.
Filed Feb 03, 2026
FY2024 10-K risk factors
46 risks
Teva generates significant revenue from generic medicines representing 57.2% of total sales in 2024. Debt stands at $17,783 million requiring substantial interest and principal payments. The company faces heavy competition and patent expirations for innovative drugs like TREANDA.
Filed Feb 05, 2025